Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males \< 12 years of age~* Subjects with severe hemophilia A~* Previously treated with FVIII for \> 50 exposure days~Exclusion Criteria:~* Subjects with current evidence of or history of inhibitors to FVIII~* Any other inherited or acquired bleeding disorder~* Platelet counts \< 100,000/mm\^3~* Creatinine \> 2x the upper limit of normal~* Aspartate aminotransferase (AST) / Alanine aminotransferase (ALT) \> 5x the upper limit of normal

- Gender: MALE
- Minimum Age: None
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Main study (Type: EXPERIMENTAL): Participants were treated and prophylaxis administered with BAY94-9027 at a dose of 25-60 international units/kilogram (IU/kg) twice per week or 45-60 IU/kg every 5 days or 60 IU/kg every 7 days as an intravenous (IV) infusion as per clinical needs of each subject up to at least 50 exposure days (EDs) and a minimum of at least 6 months.
- Part 2 (Expansion group) (Type: EXPERIMENTAL): Participants were administered with BAY94-9027 at a dose of 25-60 IU/kg twice per week for prophylaxis for 12 weeks.
- Extension study (Type: EXPERIMENTAL): Participants were treated and prophylaxis administered with BAY94-9027 at a dose of 25- 60 IU/kg twice per week or 45-60 IU/kg every 5 days or 60 IU/kg every 7 days as an IV infusion as per clinical needs of each subject for at least 50 EDs or until marketing authorization of the drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).